Illumina, Inc. is an American company. Illumina was founded in April 1998, developing and manufacturing and markets integrated systems for the analysis of genetic variation and biological function. The company offers a range of products and services that serve sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California. Illumina technology was claimed by 2014 reduced the cost of human genome sequencing to US$1000, down from the price of $1 million in 2007. Clients include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations and biotechnology companies. Illumina was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chi. While working with The Chemical Weapons Group, a venture capital firm, Bock and Stokelgel revealed what could become The Bedray technology from Elomina at Tufts University and negotiated an exclusive license for the technology. In 1999, Illumina acquired Spyder devices (founded by Michel Lebel, Richard Hutton, and Juta Eichler) for its high-productivity manufacturing technology. Illumina completed its initial public offering in July 2000.Illumina began offering polymorphic nucleotide single (SNP) genotyping services in 2001 and launched its first system, Illumina BeadLab, in 2002, using Golden Gate Genuting technology. Illumina currently offers microarray-based products and services for an expanded range of genetic analysis sequences, including SNP genotyping, gene expression and protein analysis. Elomina technologies are used by a wide range of academic and government institutions Pharmaceutical, biotechnology and other leading institutions around the world.